Essential Resources
Provider Information
From Our Sponsors
The Adult Immunization Catch-Up Schedule: A Practical Guide for Primary Care
Vaccine-preventable diseases claim up to 50,000 adult lives each year in the US. Click through this compact reminder of recommended catch up shots for your patient panel.
Adult Immunization in the US: Status, Gaps, and Forward Strategy
Adult vaccine-preventable diseases cost $26.5B annually in the US. See key gaps, barriers, and strategies primary care physicians can use to boost immunization.
Kelly Moore, MD, MPH: A Past Voting Member of the ACIP Discusses the End of Universal Recommendation for COVID-19 Vaccination
Moore, president and CEO of immunize.org, has deep roots in public health and advocacy, vaccine program implementation, and immunization education.
8 FAQs About Vaccination From Patients With Cardiovascular Disease
Based on the FAQ section in the ACC's 2025 Concise Clinical Guidance on vaccination in adults with CVD, this short slideshow also offers recommended answers.
New Vaccine Guidance from the American College of Cardiology Focuses on Adults with Heart Disease
New ACC guidance emphasizes the critical role of vaccinations in reducing infection risks and improving outcomes for adults with cardiovascular disease.
Adults Visiting the ED Are Willing to Receive Missing CDC-Recommended Vaccines, Survey Finds
More than 90% of adults making nonurgent ED visits had missed at least 1 CDC-recommended vaccine but many were willing to catch up on all of them while there.
The ACIP's Rich History of Debate is in Jeopardy, Not A Good Sign for Science, ID Expert Says
"The foundation of science in the new iteration of the ACIP is uncertain at best," William Schaffner, MD, observed. He is concerned about where that might lead.
The 5 Essential Adult Vaccines: What Your Patients Need to Know
Please remind your adult patients that these recommended vaccines (eg, pneumococcal, flu, HPV) are essential to protect them, and their communities, from serious outcomes.
Initial RSV Vaccine Uptake Low Among Older Adults, Disparities Persist, Study Reveals
Fewer than 1 in 5 eligible older adults in the US received the RSV vaccine during the first 2 seasons it was available, and uptake was lower based on SDOH.
JN.1 COVID-19 Booster Safety Confirmed in Danish Study of More than 1 Million Older Adults
Danish adults aged 65 and older at high-risk for serious infection with SARS-CoV-2 showed no increased risk of 29 serious adverse events following vaccination.
The Biggest Threat to Vaccine Confidence in the US: An Expert Discussion
Amesh Adalja, MD, urges physicians to use their trusted position to counter widespread vaccine misinformation and strengthen patient confidence in immunization.
Vaccine Hesitancy: Communication Strategies for Primary Care That Preserve Trust
Amesh Adalja, MD, infectious disease physician, outlines effective communication strategies that respect patient concerns while reinforcing physician credibility.
17 Vaccines for Adults: Who to Consider for Each
A review of 4 factors can help primary care clinicians with an initial decision about adult vaccination: health, age, lifestyle, and occupation (HALO).
Shingrix Prefilled Syringe Gets FDA Greenlight, According to GSK
The prefilled syringe presentation streamlines administration of the vaccine, eliminating the need to combine the lyophylized antigen and separate adjuvant.
FDA to Review GSK's Application for Expanded Use of RSV Vaccine in High-Risk Adults Aged 18 to 49
GSK's RSV vaccine Arexvy would join shots from Pfizer and Moderna for the younger adult population, broadening choice for those with risk factors for severe disease.
Adult Vaccines in the US: More Shots, New Dynamics on the Horizon
The adult vaccine market is poised for explosive growth, with more than 100 product launches expected over the next 10 years. Are US clinicians ready?
Nonvaccine Seasonal Flu Preventive Shows Promise in Phase 2b Clinical Trial: Cidara Therapeutics
CD388, an investigational nonvaccine antiviral, demonstrated efficacy up to 76% against influenza in a cohort of more than 5000 healthy, unvaccinated adults.
Moderna's mRNA-1010 Flu Vaccine Proves Superior Efficacy in Pivotal Late-Stage Trial
The vaccine showed superior relative vaccine efficacy that was 26.6% higher than a licensed standard-dose influenza vaccine, Moderna reported.
FDA Expands Label for Moderna's mRNA RSV Vaccine to Include At-Risk Adults Aged 18 to 59 Years
mRNA1345 (mResvia) is now indicated for adults aged 18 to 59 years with underlying conditions including cardiovascular, respiratory, and endocrine disorders.
Novavax Releases Promising Data from Descriptive Trial for COVID/Flu Combination and Stand-Alone Flu Vaccines
Both investigational vaccines induced strong immunity across all antigens and researchers reported no new safety signals, supporting phase 3 development.
The US Adult Vaccination Gap: New Analysis Quantifies the Divide, Recommends Solutions
Vaccination rates among US adults are roughly half that of pediatric populations, exposing older adults to risk for disease and complications, according to a new analysis.
Dosing Begins in Phase 2b Trial of Investigational Oral COVID-19 Vaccine Candidate
Vaxart's phase 2b trial for its oral COVID-19 vaccine follows a positive safety review and aims to enroll 10,000 participants in the US.
FDA Narrows COVID-19 Vaccine Access to High-Risk Groups, Demands New Trials for Healthy Adults
The FDA's new approach to evaluating and approving COVID-19 vaccines will move the US away from a one-size-fits-all approach and closer to policy in other countries.
Immunogenicity of Combined Flu/COVID-19 Vaccine Noninferior to Components in Older Adults
The investigational mRNA-1083 vaccine induced superior immune responses against all 4 flu strains in adults aged 50-64 years and against 3 in adults 65 and older.
Direct Mail to Older Adults at Risk for Pneumococcal Disease Improves Vaccination Rates
A mail campaign targeting adults with chronic conditions as well as their GPs increased the number receiving at least 1 shot by 9.5 percentage points.
Vaccination Attitudes in the US: Key Insights for Primary Care
A recent survey of US adults sheds light on public attitudes regarding RSV, influenza, COVID-19, MMR, and other key vaccines.
ACIP Expands RSV Vaccine Recommendation to At‑Risk Adults Aged 50–59 Years
The CDC advisory committee also endorsed GSK's pentavalent meningococcal vaccine.
GSK: 3-Year Efficacy Data for Arexvy in Older Adults Published in Lancet Respiratory Medicine
A single dose of the RSVPreF3 demonstrated a cumulative efficacy of 62.9% against RSV-LRTD across 3 seasons in adults aged 60 years and older.
Measles is Dangerous in Adults: Who and How to Assess for the MMR Booster
The 2025 measles outbreak is predominantly affecting children, but measles is highly contagious and adults remain at risk, especially if they have not received the MMR vaccination.
UK Research Collaborative Will Evaluate GSK Shingles Vaccine Effect on Dementia
GSK is partnering with the UK Dementia Research Institute and Health Data Research UK to further investigate the potential for the RZV vaccine to mitigate cognitive decline.
FDA VRBAC Meeting Cancelled, Fueling Concerns for Delays in 2025 Season Production
According to the CDC, influenza is responsible for 33 million illnesses, 430,000 hospitalizations, and 19,000 deaths so far this season.
COVID-19 2024-2025 Vaccines 33% Effective Against Hospitalization, ED Visits in Adults: Early Data
CDC midseason data suggest low COVID-19 vaccine efficacy in adults aged 18 to 64 years, with somewhat better impact on those aged 65 years and older.
WHO Recommends Flu Vaccine Composition for 2025-26 Northern Hemisphere Season as US HHS Cancels ACIP, VRBAC Meetings
Two official US vaccine planning meetings cancelled in February is an "unprecedented situation," said NFID medical director Robert Hopkins, Jr, MD.
FDA Reviewing New Prefilled Syringe Formulation for GSK’s Shingrix
An FDA decision on GSK's Shingrix application is expected by June 20, 2025.
Vaccine Distrust, Emboldened During the Pandemic, Runs Deep: An Expert Perspective
Robert Hopkins, Jr, MD, says of official communications during the COVID-19 pandemic that not enough was explained to the public about policy shifts, leaving people wondering.
Two RSV Vaccines, One Savvy Patient who Asks, "Which One do You Recommend?"
RSV vaccines from Pfizer-BioNTech and Moderna for adults aged 60 years and older aren't that different, so which would you recommend if a patient asks?
The Legacy of Vaccine Hesitancy: From COVID-19 to Flu
Vaccine hesitancy became a public health threat during the COVID-19 pandemic that lingers now and has affected uptake of other essential immunizations.
Attitudes Toward Vaccines in the Chronic Conditions Community: Survey Highlights
Hesitancy about vaccination against dangerous communicable diseases remains a public health problem, particularly when the hesitant are living with immunocompromising conditions.
RSVPreF Reduces Risk of Severe RSV in Older, High-Risk Adults in Large Real-World Study
The new research augments data on efficacy of RSVPreF in older, high-risk adults that was not captured in phase 3 pivotal clinical trials, authors said.
10 Essential Vaccine Updates for Primary Care
From ACIP updates on age eligibility and research on vaccine efficacy to US adults' attitudes toward recommended shots, these 10 at-a-glance news briefs are must-reads for PCPs.
Flu, COVID-19, RSV Vaccine Uptake Low Among US Adults in 2024-2025 Season
Many unvaccinated adults reported intent to get vaccinated, according to early season estimates released in MMWR.
The RSV Vaccine Population was Narrowed for Good Reason, says Robert Hopkins, Jr, MD, Medical Director of the NFID
ACIP recommendations for the most appropriate older population for the RSV vaccine has shifted and the NFID medical director explains why.
New Data for Arexvy Show Vaccine Efficacy Through 3 RSV Seasons in Older Adults
Data on adults aged 60 years and older who received a single dose of the RSV vaccine indicate safety and reactogenicity consistent with the overall GSK phase 3 trial program.
COVID-19 Vaccines 2024-2025: Is America Ready and Willing?
COVID-19 vaccine myths of many types remain potent enough to raise public health experts' concerns about Americans' willingness to roll up sleeves this year.
